Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant

被引:0
|
作者
Tomokazu Tamura
Takashi Irie
Sayaka Deguchi
Hisano Yajima
Masumi Tsuda
Hesham Nasser
Keita Mizuma
Arnon Plianchaisuk
Saori Suzuki
Keiya Uriu
Mst Monira Begum
Ryo Shimizu
Michael Jonathan
Rigel Suzuki
Takashi Kondo
Hayato Ito
Akifumi Kamiyama
Kumiko Yoshimatsu
Maya Shofa
Rina Hashimoto
Yuki Anraku
Kanako Terakado Kimura
Shunsuke Kita
Jiei Sasaki
Kaori Sasaki-Tabata
Katsumi Maenaka
Naganori Nao
Lei Wang
Yoshitaka Oda
Terumasa Ikeda
Akatsuki Saito
Keita Matsuno
Jumpei Ito
Shinya Tanaka
Kei Sato
Takao Hashiguchi
Kazuo Takayama
Takasuke Fukuhara
机构
[1] Hokkaido University,Department of Microbiology and Immunology, Faculty of Medicine
[2] Hokkaido University,Graduate School of Medicine
[3] Hokkaido University,School of Medicine
[4] Hokkaido University,Institute for the Advancement of Higher Education
[5] Hokkaido University,Institute for Vaccine Research and Development (IVReD)
[6] Hokkaido University,One Health Research Center
[7] Hiroshima University,Graduate School of Biomedical and Health Sciences
[8] Kyoto University,Center for iPS Cell Research and Application (CiRA)
[9] Kyoto University,Laboratory of Medical Virology, Institute for Life and Medical Sciences
[10] Hokkaido University,Department of Cancer Pathology, Faculty of Medicine
[11] Hokkaido University,Institute for Chemical Reaction Design and Discovery (WPI
[12] Kumamoto University,ICReDD)
[13] Suez Canal University,Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection
[14] Hokkaido University,Department of Clinical Pathology, Faculty of Medicine
[15] The University of Tokyo,Division of Risk Analysis and Management, International Institute for Zoonosis Control
[16] The University of Tokyo,Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science
[17] Hokkaido University,Graduate School of Medicine
[18] University of Miyazaki,Institute for Genetic Medicine
[19] University of Miyazaki,Department of Veterinary Science, Faculty of Agriculture
[20] Hokkaido University,Graduate School of Medicine and Veterinary Medicine
[21] Kyushu University,Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences
[22] Hokkaido University,Department of Medicinal Sciences, Graduate School of Pharmaceutical Sciences
[23] Hokkaido University,Division of Pathogen Structure, International Institute for Zoonosis Control
[24] Hokkaido University,Global Station for Biosurfaces and Drug Discovery
[25] University of Miyazaki,Division of International Research Promotion, International Institute for Zoonosis Control
[26] Hokkaido University,Center for Animal Disease Control
[27] The University of Tokyo,International Collaboration Unit, International Institute for Zoonosis Control
[28] The University of Tokyo,International Research Center for Infectious Diseases, The Institute of Medical Science
[29] CREST,Graduate School of Frontier Sciences
[30] Japan Science and Technology Agency,International Vaccine Design Center, The Institute of Medical Science
[31] The University of Tokyo,Collaboration Unit for Infection, Joint Research Center for Human Retrovirus Infection
[32] Kumamoto University,Kyoto University Immunomonitoring Center
[33] Kyoto University,Laboratory of Virus Control, Research Institute for Microbial Diseases
[34] AMED-CREST,Division of Molecular Pathobiology, International Institute for Zoonosis Control
[35] Japan Agency for Medical Research and Development (AMED),School of Medicine
[36] Osaka University,Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection
[37] Hokkaido University,undefined
[38] Kobe University,undefined
[39] Tokyo Metropolitan Institute of Public Health,undefined
[40] Tokai University School of Medicine,undefined
[41] Kyoto University,undefined
[42] Kumamoto University,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Circulation of SARS-CoV-2 Omicron XBB has resulted in the emergence of XBB.1.5, a new Variant of Interest. Our phylogenetic analysis suggests that XBB.1.5 evolved from XBB.1 by acquiring the S486P spike (S) mutation, subsequent to the acquisition of a nonsense mutation in ORF8. Neutralization assays showed similar abilities of immune escape between XBB.1.5 and XBB.1. We determine the structural basis for the interaction between human ACE2 and the S protein of XBB.1.5, showing similar overall structures between the S proteins of XBB.1 and XBB.1.5. We provide the intrinsic pathogenicity of XBB.1 and XBB.1.5 in hamsters. Importantly, we find that the ORF8 nonsense mutation of XBB.1.5 resulted in impairment of MHC suppression. In vivo experiments using recombinant viruses reveal that the XBB.1.5 mutations are involved with reduced virulence of XBB.1.5. Together, our study identifies the two viral functions defined the difference between XBB.1 and XBB.1.5.
引用
收藏
相关论文
共 50 条
  • [31] Virological characteristics of SARS-CoV-2 Omicron BA.5.2.48
    Wang, Wenqi
    Jin, Qiushi
    Liu, Ruixue
    Zeng, Wentao
    Zhu, Pengfei
    Li, Tingting
    Wang, Tiecheng
    Xiang, Haiyang
    Zhang, Hang
    Chen, Qin
    Gao, Yun
    Lai, Yana
    Yan, Fang
    Xia, Xianzhu
    Li, Jianmin
    Wang, Xuefeng
    Gao, Yuwei
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [32] A commentary on 'Re-emergence of SARS-CoV-2 Omicron subvariant XBB.1.5: present status, treatment, and future outlook-2023'
    Chiu, Si-Un Frank
    Chen, Jiun-Rung
    Chiu, Chong-Chi
    INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (10) : 3197 - 3198
  • [33] Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
    Pung, Rachael
    Kong, Xin Peng
    Cui, Lin
    Chae, Sae-Rom
    Chen, Mark I-Cheng
    Lee, Vernon J.
    Ho, Zheng Jie Marc
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2023, 37
  • [34] Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike
    Yamasoba, Daichi
    Kimura, Izumi
    Nasser, Hesham
    Morioka, Yuhei
    Nao, Naganor
    Ito, Jumpei
    Uriu, Keiya
    Tsuda, Masumi
    Zahradnik, Jiri
    Shirakawa, Kotaro
    Suzuki, Rigel
    Kishimoto, Mai
    Kosugi, Yusuke
    Kobiyama, Kouji
    Hara, Teppei
    Toyoda, Mako
    Tanaka, Yuri L.
    Butlertanaka, Erika P.
    Shimizu, Ryo
    Ito, Hayato
    Wang, Lei
    Oda, Yoshitaka
    Orba, Yasuko
    Sasaki, Michihito
    Nagata, Kayoko
    Yoshimatsu, Kumiko
    Asakura, Hiroyuki
    Nagashima, Mami
    Sadamasu, Kenji
    Yoshimura, Kazuhisa
    Kuramochi, Jin
    Seki, Motoaki
    Fujiki, Ryoji
    Kaneda, Atsushi
    Shimada, Tadanaga
    Nakada, Taka-aki
    Sakao, Seiichiro
    Suzuki, Takuji
    Ueno, Takamasa
    Takaori-Kondo, Akifumi
    Ishii, Ken J.
    Schreiber, Gideon
    Sawa, Hirofumi
    Saito, Akatsuki
    Irie, Takashi
    Tanaka, Shinya
    Matsuno, Keita
    Fukuhara, Takasuke
    Ikeda, Terumasa
    Sato, Kei
    CELL, 2022, 185 (12) : 2103 - +
  • [35] Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological characteristics
    Kimura, Izumi
    Yamasoba, Daichi
    Nasser, Hesham
    Ito, Hayato
    Zahradnik, Jiri
    Wu, Jiaqi
    Fujita, Shigeru
    Uriu, Keiya
    Sasaki, Jiei
    Tamura, Tomokazu
    Suzuki, Rigel
    Deguchi, Sayaka
    Plianchaisuk, Arnon
    Yoshimatsu, Kumiko
    Kazuma, Yasuhiro
    Mitoma, Shuya
    Schreiber, Gideon
    Asakura, Hiroyuki
    Nagashima, Mami
    Sadamasu, Kenji
    Yoshimura, Kazuhisa
    Takaori-Kondo, Akifumi
    Ito, Jumpei
    Shirakawa, Kotaro
    Takayama, Kazuo
    Irie, Takashi
    Hashiguchi, Takao
    Nakagawa, So
    Fukuhara, Takasuke
    Saito, Akatsuki
    Ikeda, Terumasa
    Sato, Kei
    JOURNAL OF VIROLOGY, 2023, 97 (10)
  • [36] An XBB.1.5-based inactivated SARS-CoV-2 vaccine partially protects against XBB.1.5 and JN.1 strains in hamsters
    Ryuta Uraki
    Mutsumi Ito
    Maki Kiso
    Kiyoko Iwatsuki-Horimoto
    Masafumi Endo
    Seiya Yamayoshi
    Yoshihiro Kawaoka
    npj Viruses, 3 (1):
  • [37] Virological characteristics of the SARS-CoV-2 KP.2 variant
    Kaku, Yu
    Uriu, Keiya
    Kosugi, Yusuke
    Okumura, Kaho
    Yamasoba, Daichi
    Uwamino, Yoshifumi
    Kuramochi, Jin
    Sadamasu, Kenji
    Yoshimura, Kazuhisa
    Asakura, Hiroyuki
    Nagashima, Mami
    Ito, Jumpei
    Sato, Kei
    LANCET INFECTIOUS DISEASES, 2024, 24 (07): : e416 - e416
  • [38] Predictors of disease severity in SARS-CoV-2 omicron variant XBB sublineages and variants of interest
    Ngiam, Jinghao Nicholas
    Ng, Oon Tek
    Toh, Matthias Paul Han Sim
    Gao, Qi
    Soong, Ai Jia
    Teo, Joel Han Wen
    Low, Shannon
    Vasoo, Shawn
    Li, Jia Hui
    Thoon, Koh Cheng
    Oh, Helen
    Pada, Surinder Kaur M. S.
    Ooi, Say Tat
    Soh, Jade
    Wong, Hei Man
    Tambyah, Paul Anantharajah
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (11)
  • [39] Predicting changes in neutralizing antibody activity for SARS-CoV-2 XBB.1.5 using in silico protein modeling
    Ford, Colby T.
    Yasa, Shirish
    Machado, Denis Jacob
    White III, Richard Allen
    Janies, Daniel A.
    FRONTIERS IN VIROLOGY, 2023, 3
  • [40] Airborne Transmission of the SARS-CoV-2 Delta Variant and the SARS-CoV-2 Omicron Variant
    Lee, Byung Uk
    AEROSOL AND AIR QUALITY RESEARCH, 2022, 22 (01)